Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaven I&g 4 Regulatory News (MAV4)

Share Price Information for Maven I&g 4 (MAV4)

Share Price is delayed by 15 minutes
Get Live Data
50.00    0.00 (0.00%)
Bid:
49.00
Ask:
51.00
Spread: 2.00 (4.082%)
Market Cap: £83.71m
MAV4 Live PriceLast checked at - London Stock Exchange

Intraday Maven I&g 4 Share Chart

Issue of Equity - Replacement

7 Apr 2025 07:00

RNS Number : 8191D
Maven Income & Growth VCT 4 PLC
06 April 2025
 

Maven Income and Growth VCT 4 PLC (the Company)

 

Issue of Equity - Replacement announcement

 

The issuer advises of an amendment to the Issue of Equity announcement and that the following replaces the Maven Income and Growth VCT 4 PLC announcement released at 18.18 BST on 4 April 2025 under RNS No. 8096D.

 

The reference to the total amount of valid applications has been amended to £2,044,066; the total number of shares issued has been amended to 3,338,726; the range of offer prices at which the shares were issued has been amended to 59.47p to 61.05p per Ordinary Share; and the Ordinary Shares now in issue, and the total voting rights, have been amended to 154,982,952. All other details remain unchanged.

 

The full amended version is shown below.

 

Maven Income and Growth VCT 4 PLC (the Company)

 

Issue of Equity

 

On 27 September 2024, the Company launched an offer for subscription for new ordinary shares of 10p each (Ordinary Shares) to raise up to £5 million, with an over-allotment facility for up to a further £5 million (the Offer). As announced on 1 April 2025, the Company's Offer is now fully subscribed and closed to further applications.

 

Pursuant to the Offer, £2,044,066 of valid applications were received in the period from 9.00am on 24 March 2025 up to and including 9.00am on 1 April 2025 in respect of the 2024/2025 tax year. As a result, the Company has issued and allotted 3,338,726 new Ordinary Shares on 4 April 2025. In accordance with the allotment formula set out in the prospectus for the Offer, the offer prices at which the shares were issued were in the range of 59.47p to 61.05p per Ordinary Share and, as a result, the number of Ordinary Shares now in issue is 154,982,952. Therefore, the total number of voting rights in the Company is 154,982,952 and this may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

In respect of this allotment, an application will be made by the Company to the FCA and to the London Stock Exchange for the new Ordinary Shares to be admitted to the Official List and to trading on the London Stock Exchange's main market for listed securities. It is expected that the admission of the new Ordinary Shares will become effective, and dealings will commence, on or around 9 April 2025.

 

This is the fourth and final allotment in respect of 2024/2025 tax year. It is intended that an allotment in respect of applications for the 2025/2026 tax year will take place on, or before, 2 May 2025.

 

For further information, please contact:

 

Maven Capital Partners UK LLP

Telephone: 0141 306 7400

E-mail: enquiries@mavencp.com

 

Maven Capital Partners UK LLP

Secretary

 

4 April 2025

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOESSAFFMEISESL
Date   Source Headline
20th May 202610:12 amRNSAdmission of Further Securities to Trading
15th May 202610:45 amRNSDirector/PDMR Shareholding
15th May 202610:41 amRNSIssue of Equity - Dividend Investment Scheme
14th May 20265:22 pmRNSTransaction in Own Shares
12th May 20263:37 pmRNSUnaudited NAV - Dividend Investment Scheme
7th May 20261:45 pmRNSResult of AGM
30th Apr 202610:58 amRNSAdmission of Further Securities to Trading
29th Apr 202612:29 pmRNSIssue of Equity
20th Apr 202612:23 pmRNSPublication of a Supplementary Prospectus
15th Apr 202611:27 amRNSAdmission of Further Securities to Trading
14th Apr 202611:09 amRNSIssue of Equity
10th Apr 202612:02 pmRNSUnaudited Net Asset Value
8th Apr 20269:33 amRNSAdmission of Further Securities to Trading
25th Mar 20263:51 pmRNSTransaction in Own Shares
25th Mar 202610:55 amRNSAdmission of Further Securities to Trading
24th Mar 202612:11 pmRNSIssue of Equity
19th Mar 20264:21 pmRNSUnaudited NAV and Proposed Final Dividend
18th Feb 20264:58 pmRNSAdmission of Further Securities to Trading
17th Feb 202611:07 amRNSDirector/PDMR Shareholding
17th Feb 202611:07 amRNSDirector/PDMR Shareholding
17th Feb 202610:54 amRNSIssue of Equity
4th Feb 20267:00 amRNSStatement re Offer for Subscription
21st Jan 202611:07 amRNSAdmission of Further Securities to Trading
20th Jan 20262:05 pmRNSAdmission of Further Securities to Trading
16th Jan 20269:52 amRNSDirector/PDMR Shareholding
16th Jan 20269:44 amRNSIssue of Equity
15th Jan 202610:36 amRNSDirector/PDMR Shareholding
15th Jan 202610:35 amRNSDirector/PDMR Shareholding
15th Jan 20269:55 amRNSIssue of Equity
14th Jan 20262:39 pmRNSUnaudited NAV - Dividend Investment Scheme
13th Jan 202612:10 pmRNSUnaudited Net Asset Value
4th Dec 202510:35 amRNSSecond Interim Dividend
18th Nov 20253:48 pmRNSTransaction in Own Shares
14th Nov 20259:31 amRNSNet Asset Value(s)
13th Nov 20254:53 pmRNSResult of General Meeting
2nd Oct 20254:42 pmRNSPublication of a Prospectus
29th Aug 20257:00 amRNSDirector/PDMR Shareholding
29th Aug 20257:00 amRNSIssue of Equity
29th Aug 20257:00 amRNSHalf-year Report
20th Aug 20252:14 pmRNSStatement re Dividend Investment Scheme
31st Jul 20254:42 pmRNSTransaction in Own Shares
16th Jul 202510:18 amRNSStatement re Unaudited NAV and Interim Dividend
16th Jul 20257:08 amRNSStatement re Offer for Subscription
21st May 20254:44 pmRNSTransaction in Own Shares
16th May 20259:30 amRNSDirector/PDMR Shareholding
16th May 20259:26 amRNSIssue of Equity - Dividend Investment Scheme
9th May 20251:53 pmRNSStatement re Dividend Investment Scheme
9th May 202510:03 amRNSNet Asset Value(s)
8th May 20251:43 pmRNSResult of AGM
6th May 202511:55 amRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.